Reply to T.G. Karrison

Comment

Dmitry A Nosov et al. J Clin Oncol. 2013.

. 2013 Feb 20;31(6):814-5.

doi: 10.1200/JCO.2012.46.4826.

No abstract available

Comment on

Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA, Esteves B, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Doval DC, Strahs A, Slichenmyer WJ, Bhargava P. Nosov DA, et al. J Clin Oncol. 2012 May 10;30(14):1678-85. doi: 10.1200/JCO.2011.35.3524. Epub 2012 Apr 9. J Clin Oncol. 2012. PMID: 22493422 Clinical Trial.
Estimation of progression-free survival in the randomized discontinuation trial design.
Karrison TG. Karrison TG. J Clin Oncol. 2013 Feb 20;31(6):814. doi: 10.1200/JCO.2012.46.1087. Epub 2013 Jan 14. J Clin Oncol. 2013. PMID: 23319693 No abstract available.